Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63. https://doi.org/10.3322/caac.21834

Pantziarka P, Capistrano R, De Potter A, Vanderborne L, Bouche G. An Open Access Database of Licensed Cancer Drugs. Frontiers in Pharmacology. 2021;12:627574. https://doi.org/10.3389/fphar.2021.627574

Luqmani YA. Mechanisms of Drug Resistance in Cancer Chemotherapy. Med Princ Prac. 2005;14:35-48. https://doi.org/10.1159/000086183

Persidis A. Cancer multidrug resistance. Nature Biotech. 1999;17:94-5. https://doi.org/10.1038/5289

Cortes JE, Pazdur R. Docetaxel. J Clin Onc. 1995;13:2643-55. https://doi.org/10.1200/JCO.1995.13.10.2643

Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr. Jones JA, Taplin ME. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New Eng J Med. 2004;351:1513-20. https://doi.org/10.1056/NEJMoa041318

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostatecancer. The New Eng J Med. 2004;351:1502-12. https://doi.org/10.1056/NEJMoa040720

Laurens V, Magadoux L, Isambert N, Plenchette S, Jeannin JF. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer. Int J Onc. 2014;45:919-28. https://doi.org/10.3892/ijo.2014.2517

Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem, 2007;2:920-42. https://doi.org/10.1002/cmdc.200600308

Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Onc. 2011;8:12-23. https://doi.org/10.1038/nrclinonc.2010.136

Harris KA, Reese DM. Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 2001;61:2177-92. https://doi.org/10.2165/00003495-200161150-00003

Powles TJ. Evolving clinical strategies: innovative approaches to the use of mitoxantrone-introduction. Eur J Cancer Care. 1997;6(4):1-3. https://doi.org/10.1111/j.1365-2354.1997.tb00317.x

Rigacci L, Carpaneto A, Alterini R, Carrai V, Bernardi F, Bellesi G, Longo G, Bosi A, Rossi FP. Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: longterm follow-up results. Cancer. 2003;97:97-104. https://doi.org/10.1002/cncr.11032

Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, Austin CA. Murine transgenic cells lacking DNA topoisomerase II b are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharm. 1999;56:1309-16. https://doi.org/10.1124/mol.56.6.1309

Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Alterations in the topoisomerase II a gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II b enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Can Res. 1995;55:1707-16.

Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and druginduced DNA cleavage in association with reduced expression of the topoisomerase II b isoform. Biochemistry. 1991;30:9953-61. https://doi.org/10.1021/bi00105a020

Zhou R, Wang Y, Gruber A, Larsson R, Castanos-Velez E, Liliemark E. Topoisomerase II-mediated alterations of K562 drug resistant sublines. Med Onc. 1999:16(3):191-8. https://doi.org/10.1007/BF02906131

Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020;21(9):3233. https://doi.org/10.3390/ijms21093233

Shinozaki K, Yamaguchi-Shinozaki K. Molecular responses to dehydration and low temperature: differences and cross-talk between two stress signaling pathways. Curr Opin Plant Biol. 2000;3:217-23. https://doi.org/10.1016/S1369-5266(00)80068-0

Schroeder JI, Kwak JM, Allen GJ. Guard cell ABA signalling and engineering drought hardiness in plants. Nature. 2001:410:327-30. https://doi.org/10.1038/35066500

Li HH, Hao RL, Wu SS, Guo PC, Chen CJ, Pan LP, Ni H. Occurrence, function and potential medicinal applications of the phytohormone ABA in animals and humans. Biochem Pharm. 2011;82:701-12. https://doi.org/10.1016/j.bcp.2011.06.042

Sakthivel P, Sharma N, Klahn P, Gereke M, Bruder D. ABA: a phytohormone and mammalian cytokine as novel pharmacon with potential for future development into clinical applications. Curr Med Chem. 2016;23:1549-70 . https://doi.org/10.2174/0929867323666160405113129

Jung Y, Cackowski FC, Yumoto K, Decker AM, Wang Y, Hotchkin M, Lee E, Buttitta L, Taichman RS. Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase. Neoplasia. 2021;23:102-11. https://doi.org/10.1016/j.neo.2020.11.009

Zhou N, Yao Y, Ye H, Zhu W, Chen L, Mao Y. Abscisic-acid-induced cellular apoptosis and differentiation in glioma via the retinoid acid signaling pathway. Int J Can. 2016;138:1947-58. https://doi.org/10.1002/ijc.29935

Erdogan S, Doganlar O, Doganlar ZB, Serttas R, Turkekul K, Dibirdik I, Bilir A. The flavonoid apigenin reduces prostate cancer CD44+ stem cell survival and migration through PI3K/Akt/NF-κB signaling. Life Sciences. 2016;162:77-86. https://doi.org/10.1016/j.lfs.2016.08.019

Lockhart CA, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy. Mol Cancer Ther. 2003;2:685-98.

Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen independent prostate cancer treated with docetaxel. Clin Cancer Res. 2008;14(14):4543-9. https://doi.org/10.1158/1078-0432.CCR-07-4230

Moreira JMA, Lima TS, Iglesias-Gato D, Souza LDO, Stenvang, Lima JDS, Røder MA, Brasso K. Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. Cancers. 2021;13:1290. https://doi.org/10.3390/cancers13061290

Llesuy SF, Arnaiz SL. Hepatotoxicity of mitoxantrone and doxorubicin. Toxicology. 1990;63(2):187-98. https://doi.org/10.1016/0300-483X(90)90042-F

Marzec M, Eletto D, Argon Y. GRP94: an HSP90-like protein specialized for protein folding and quality control in the Endoplasmic Reticulum. Biochim Biophys Acta. 2012;1823(3):774-87. https://doi.org/10.1016/j.bbamcr.2011.10.013

Amankwah YS, Collins P, Fleifil Y, Unruh, E, Márquez KJR, Vitou K, Kravats AN. Grp94 Works Upstream of BiP in Protein Remodeling Under Heat Stress. J Mol Biol. 2022;19:167762. https://doi.org/10.1016/j.jmb.2022.167762

Kadowaki H, Nishitoh H. Signaling Pathways from the Endoplasmic Reticulum and Their Roles in Disease. Genes. 2013;4:306-33. https://doi.org/10.3390/genes4030306

Kobayashi N, Takada Y, Hachiya M, Ando K, Nakajima N, Akashi M. Tnf-α Induced p21WAF1 but Not BAX in Colon Cancer Cells WiDr With Mutated p53: Important Role of Protein Stabilization. Cytokine. 2000;12:1745-54. https://doi.org/10.1006/cyto.2000.0782

Cho EK, Hong CB. Over-expression of tobacco NtHSP70-1 contributes to drought-stress tolerance in plants. Plant Cell Rep. 2006;25:349-58. https://doi.org/10.1007/s00299-005-0093-2

Volkov RA, Panchuk II, Mullineaux PM, Schoffl F. Heat stress-induced H2O2 is required for effective expression of heat shock genes in Arabidopsis. Plant Mol Biol. 2006;61:733-46. https://doi.org/10.1007/s11103-006-0045-4

Hu XL, Liu RX, Li YH, Wang W, Tai FJ, Xue RL, Li CH. Heat shock protein 70 regulates the ABA-induced antioxidant response of maize to combined drought and heat stress. Plant Growth Reg. 2010;60:225-35. https://doi.org/10.1007/s10725-009-9436-2